GH1 and pituitary tumor: Somatoprim is a compound, not yet commercially available, that binds to human sstr2, sstr4, and sstr5, proven in vitro to reduce GH secretion from GH-secreting pituitary tumors and devoid of significant effects on insulin and glucagone secretion (74).